1. Pink Sheet

With Perjeta, The Cost Of HER2 Breast Cancer Therapy Goes Up

 
• By Jessica Merrill

Roche’s Perjeta will be priced at a premium to Herceptin and used in combination with it, more than doubling the cost of treating patients with HER2-positive metastatic breast cancer.

Roche/Genentech Inc. will launch its new HER2-positive breast cancer drug Perjeta (pertuzumab) at a 31% premium to the price of its existing gold standard Herceptin (trastuzumab), an aggressive strategy that will substantially increase the cost of treating patients with metastatic HER2-positive breast cancer – especially because Perjeta is to be given in conjunction with Herceptin.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

EU ‘Can’t Expect Industry To Give Up Proprietary Insights’ Under Health Data & Clinical Trials Regulations

 
• By Eliza Slawther

Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.

How Tumult At US FDA Could Impact Merger and Acquisition Strategy

 
• By Joseph Haas and Nielsen Hobbs

With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.